# FDA 483 - Unknown Company - March 31, 2010

Source: https://www.keypedia.com/records/483/unknown-company/e1a9e117-61e0-42d7-bbd1-2d2093cbda41

> FDA 483 for Unknown Company on March 31, 2010. Product: Drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Inspection Date: 2010-03-31
- Product Type: Drugs
- Office Name: New York District Office
- Summary: This FDA Form 483 document details observations made during an inspection, indicating deficiencies in the firm's operations and quality systems.

Observation 1 states that the firm failed to establish an adequate quality control unit. This suggests a fundamental issue with the oversight and management of quality-related activities, which is critical for ensuring product safety and efficacy.

Observation 2 notes that the firm did not adequately validate the manufacturing process for Product X. Process validation is a regulatory requirement to ensure that a manufacturing process consistently produces a product meeting its predetermined specifications and quality attributes. The lack of adequate validation implies that the quality and consistency of Product X cannot be reliably assured.

Observation 3 indicates that the firm did not maintain proper records of equipment cleaning and maintenance. Accurate and complete records are essential for demonstrating that equipment is maintained in a suitable condition for its intended use and that cross-contamination or other quality issues are prevented. This deficiency points to a breakdown in good manufacturing practices (GMP) related to facility and equipment control.

Collectively, these observations highlight significant quality system and manufacturing issues, including inadequate quality control, insufficient process validation, and poor record-keeping. These findings suggest potential non-compliance with regulatory requirements and could have business and operational implications, potentially requiring corrective actions, re-inspections, and impacting product release or market access.

## Related Documents

- [483 - 2011-05-05](https://www.keypedia.com/records/483/unknown-company/8f74a6dc-c0a5-4354-8036-3890202fc8eb)
- [RESUME - Unknown Date](https://www.keypedia.com/records/resume/unknown-company/f071af8e-ce6c-4c87-947b-39d97b8c2137)
- [483 - 2023-07-14](https://www.keypedia.com/records/483/unknown-company/ab0a6d0b-c0ca-4e02-82e2-ad2098b7fe12)
- [483 - 2017-08-09](https://www.keypedia.com/records/483/unknown-company/c9125a20-c458-41ce-a15c-b212897a235f)
- [483 - 2011-03-18](https://www.keypedia.com/records/483/unknown-company/da4f7d5a-691d-4aff-8e4f-02abadace162)

## Related Officers

- [Supervisory Toxicologist at the Food & Drug Administration (FDA) Center for Tobacco Products (CTP)](https://www.keypedia.com/people/chad-n/a953f041-d9a2-4f99-b4a6-d6380597bbf1)
- [Fixer / Author / Managing Partner - Forest Hill Labs, Forest Hill Consulting / Investing some of my time in others](https://www.keypedia.com/people/robert-horem/d7ff1a47-dd60-4a80-978f-bc22e531d500)
- [Investigator -Federal Program Manager](https://www.keypedia.com/people/chad-n-thompson/f99444f7-cffb-43d0-b102-315d12115b9e)

Office: https://www.keypedia.com/offices/new-york-district-office/9fa3d265-16ca-438d-8a6e-b47f60dc260d